Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

Glutamine/Arginine/Carnitine in all strengths

Lack of Processing Controls; Environmental sampling revealed 1 CFU (Colony Forming Unit) identified as Talaromyces rotundus, a fungi.

Terminated cGMP deviation Coast Quality Pharmacy, LLC dba Anazao Health D-0579-2020
Class II · Moderate risk

Clear Eyes Redness Relief Hand Pocket Pal Tray Display

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1835-2019
Class II · Moderate risk

Clear eyes REDNESS RELIEF

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1834-2019
Class II · Moderate risk

Clear Eyes Maximum Redness Relief Club Pack Display

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1831-2019
Class II · Moderate risk

Clear Eyes Redness Relief Club Pack Display

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1829-2019
Class II · Moderate risk

Clear Eyes Assorted Sidekick Floor Stand Display

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1828-2019
Class II · Moderate risk

Clear Eyes Assorted IRC Display

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1826-2019
Class II · Moderate risk

Clear eyes MAXIMUM REDNESS RELIEF

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1825-2019
Class II · Moderate risk

Clear eyes MAXIMUM ITCHY EYE RELIEF

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1824-2019
Class II · Moderate risk

Clear eyes REDNESS RELIEF

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1823-2019
Class II · Moderate risk

Clear eyes REDNESS RELIEF

CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.

Terminated cGMP deviation Medtech Products, Inc. D-1822-2019
Class II · Moderate risk

Mometasone Furoate Cream USP

GMP Deviations: Glenmark received complaints stating that mometasone fuorate cream was gritty.

Terminated cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-192-17 D-1586-2019